Aldo Scarpa,David K Chang,Katia Nones,Vincenzo Corbo,Ann-Marie Patch,Peter Bailey,Rita T Lawlor,Amber L Johns,David K Miller,Andrea Mafficini,Borislav Rusev,Maria Scardoni,Davide Antonello,Stefano Barbi,Katarzyna O Sikora,Sara Cingarlini,Caterina Vicentini,Skye McKay,Michael C J Quinn,Timothy J C Bruxner,Angelika N Christ,Ivon Harliwong,Senel Idrisoglu,Suzanne McLean,Craig Nourse,Ehsan Nourbakhsh,Peter J Wilson,Matthew J Anderson,J Lynn Fink,Felicity Newell,Nick Waddell,Oliver Holmes,Stephen H Kazakoff,Conrad Leonard,Scott Wood,Qinying Xu,Shivashankar Hiriyur Nagaraj,Eliana Amato,Irene Dalai,Samantha Bersani,Ivana Cataldo,Angelo P Dei Tos,Paola Capelli,Maria Vittoria Davì,Luca Landoni,Anna Malpaga,Marco Miotto,Vicki L J Whitehall,Barbara A Leggett,Janelle L Harris,Jonathan Harris,Marc D Jones,Jeremy Humphris,Lorraine A Chantrill,Venessa Chin,Adnan M Nagrial,Marina Pajic,Christopher J Scarlett,Andreia Pinho,Ilse Rooman,Christopher Toon,Jianmin Wu,Mark Pinese,Mark Cowley,Andrew Barbour,Amanda Mawson,Emily S Humphrey,Emily K Colvin,Angela Chou,Jessica A Lovell,Nigel B Jamieson,Fraser Duthie,Marie-Claude Gingras,William E Fisher,Rebecca A Dagg,Loretta M S Lau,Michael Lee,Hilda A Pickett,Roger R Reddel,Jaswinder S Samra,James G Kench,Neil D Merrett,Krishna Epari,Nam Q Nguyen,Nikolajs Zeps,Massimo Falconi,Michele Simbolo,Giovanni Butturini,George Van Buren,Stefano Partelli,Matteo Fassan,Kum,Anthony J Gill,David A Wheeler,Richard A Gibbs,Elizabeth A Musgrove,Claudio Bassi,Giampaolo Tortora,Paolo Pederzoli,John V Pearson,Nicola Waddell,Andrew V Biankin,Sean M Grimmond

Corrigendum: Case report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer

Corrigendum: CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth

Erratum: Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients

Corrigendum: Case report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient

Erratum to: Extended Disease Control with Unconventional Cabozantinib Dose Increase in Metastatic Renal Cell Carcinoma

Corrigendum to "Analysis and Management of Rituximab Resistance in PLA2R1-Associated Membranous Nephropathy" [ Kidney International Reports Volume 6, Issue 4, April 2021, Pages 1183-1188]

Corrigendum: Management of metastatic endometrial cancer: physicians’ choices beyond the first line after approval of checkpoint inhibitors

Corrigendum: Bevacizumab-Irinotecan combination therapy in recurrent low-grade glioma, previously treated with chemo-radiotherapy: a case report

Corrigendum: Targeting HER3 to overcome RGFR TKI resistance in NSCLC

Corrigendum to "A Novel Inhibitor of MDM2 Oncogene Blocks Metastasis of Hepatocellular Carcinoma and Overcomes Chemoresistance" [genes Dis 694 (2019) 419-430].

Corrigendum: Surgical decision-making following neoadjuvant immunotherapy for dMMR rectal cancer; case reports and review of the literature

Correction: A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11

Erratum: Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab

Corrigendum to “Chaperone-Mediated Autophagy Markers LAMP2A and HSC70 Are Independent Adverse Prognostic Markers in Primary Resected Squamous Cell Carcinomas of the Lung”

Corrigendum: TP53 co-mutations in advanced lung adenocarcinoma: comparative bioinformatic analyses suggest ambivalent character on overall survival alongside KRAS, STK11 and KEAP1 mutations

Corrigendum: CD317-Positive Immune Stromal Cells in Human “Mesenchymal Stem Cell” Populations

Erratum: Author correction to 'VEGFR2-targeted antibody fused with IFNamut regulates the tumor microenvironment of colorectal cancer and exhibits potent anti-tumor and anti-metastasis activity' [Acta Pharm Sin B 11 (2021) 420-433]

Corrigendum: EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy As First-Line Therapy for Non-Small Cell Lung Cancer Patients with the L858R Point Mutation.

Corrigendum: Whole-genome Landscape of Pancreatic Neuroendocrine Tumours.

Correction: Lepore Signorile et al. c-MYC Protein Stability Is Sustained by MAPKs in Colorectal Cancer. Cancers 2022, 14, 4840

Corrigendum: Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study